Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 14/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | BACE2 | Q9Y5Z0 | 6/20 | 0.33 |
| ▸ | CTSD | P07339 | 6/20 | 0.33 |
| ▸ | REN | P00797 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4520219 | 0.90 | BACE1 (0.45) | BACE1APPBACE2CTSDREN | |
| SCHEMBL4532322 | 0.81 | APP (0.46) | BACE1APPBACE2CTSDREN | |
| SCHEMBL4924630 | 0.80 | BACE1 (0.42) | BACE1APPBACE2CTSDREN | |
| SCHEMBL4522295 | 0.78 | APP (0.42) | BACE1APPBACE2CTSD | |
| SCHEMBL4527752 | 0.77 | APP (0.44) | BACE1APPBACE2CTSDREN | |
| SCHEMBL4528183 | 0.77 | APP (0.42) | BACE1APPBACE2CTSDREN | |
| SCHEMBL4510675 | 0.76 | BACE1 (0.55) | BACE1APPBACE2CTSDREN | |
| SCHEMBL4525846 | 0.76 | BACE1 (0.48) | BACE1APPBACE2CTSDREN | |
| SCHEMBL4516942 | 0.76 | BACE1 (0.46) | BACE1APPBACE2CTSDREN | |
| SCHEMBL4513499 | 0.75 | BACE1 (0.42) | BACE1APPBACE2CTSDREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293718-A1 | Novel 2-Amino-Imidazole-4-One Compounds and Their Use in the Manufacture of a Medicament to Be Used in the Treatment of Cognitive Impairment, Alzheimer's Disease, Neurodegeneration and Dementia | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293718-A1 | Novel 2-Amino-Imidazole-4-One Compounds and Their Use in the Manufacture of a Medicament to Be Used in the Treatment of Cognitive Impairment, Alzheimer's Disease, Neurodegeneration and Dementia | PSEN2, MAPT, PSEN1 | BACE1 14/4885APP 27/4885BACE2 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.